Fig. 1From: Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trialGenomic landscape of GC patients in response to ramucirumab. a Genomic landscape of gastric cancer patients with waterfall plot of response to ramucirumab (top panel). The y-axis represents the percentage of maximum tumor reduction assessed according to RECIST 1.1 criteria. The lower dotted line represents tumor reduction of 30%, as per RECIST, representing partial response (PR). The bar graphs are colored based on TCGA molecular classification. The first middle panel represents age distribution, the second middle panel depicts overall mutational burden (non-synonymous mutation), the third middle panel shows histopathological classification, the fourth panel demonstrates HER2 expression level, the fifth panel demonstrates objective response rate to ramucirumab and paclitaxel response, and the last middle panel represents mutational signatures. The bottom panel demonstrates mutational landscape. b Swimmer plot. Each lane represents a single patient’s data. The x-axis represents the duration of ramucirumab therapy for each patientBack to article page